MenFive is the result of a 13-year-collaboration between India’s Serum Institute and the global health organisation PATH. Funded by the UK, MenFive is the first conjugate vaccine that protects against the A, C, W, Y and X serogroups of the meningococcal meningitis infection. The X serogroup is the new type which is increasingly predominant in African outbreaks which can kill children in a matter of hours.

World Health Organization (WHO) has judged MenFive safe, effective and affordable.

Read the full article.